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AbsTrAcT
Travelling during pregnancy has become increasingly common. Many pregnant women travel for pleasure 
and recreation and a lot of them continue to work and therefore often travel on business, sometimes to 
areas with poor standards of sanitation and limited access to health care providers. During pregnancy, 
it is extremely important that a woman has a regular access to maternal health care, also in temporary 
destinations, especially in areas characterised by harsh environmental conditions, and places where 
the prevalence of infectious diseases is high. It must be remembered that the course of contagious or 
parasitic illnesses, such as hepatitis E and malaria, is generally more severe in pregnant travellers, due 
to pregnancy-related immunosuppression. The assessment of indications and contraindications for the 
use of mandatory/recommended vaccinations and antimalarial drugs is also very important in pregnant 
travellers. When pregnant women travel for long term, it is absolutely necessary that they receive prenatal 
care in a new place of residence. Scheduled maternity care usually begins in week 10–12 of pregnancy, 
and continues once a month until the 7 month of pregnancy, next every second week until week 36 and 
then once a week until the delivery. 
(Int Marit Health 2018; 69, 1: 63–69)
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INTrODUcTION
Before going abroad, a pregnant woman should undergo 
a thorough medical examination. During a pre-travel consul-
tation, a physician should take into account the following 
factors: all the relevant information regarding the current 
pregnancy, pre-existing medical conditions (e.g. chronic 
diseases), the current health status of a pregnant patient 
as well as the access to health care providers and major 
risk factors (transmission of infectious diseases) in the des-
tination area [1–3]. It must be remembered that the course 
of contagious and parasitic illnesses, such as hepatitis E 
or malaria, is generally more severe in pregnant travellers, 
due to pregnancy-related immunosuppression [4, 5]. It is 
also important to appropriately assess the indications and 
contraindications for the administration of mandatory/rec-
ommended vaccinations and the use of antimalarial drugs 
[6, 7]. Before travelling overseas, pregnant women are rec-
ommended to obtain an extended insurance policy covering 
the costs of treatment and repatriation as well as the costs 
of care of the newborn (a majority of insurance plans do not 
account for complications of pregnancy and delivery). They 
are also advised to check if the air or maritime transport 
operators are planning any special requirements or pro-
cedures applying to pregnant travellers. When travelling 
abroad expectant mothers must remember to take a copy 
of their pregnancy medical records including the information 
on the expected date of delivery, notes on prenatal care 
and the information on indications and contraindications 
for travel. They should carry a travel health kit containing 
all the necessary medications (antiemetic drugs, antacids, 
medications for the treatment of vaginitis) (Table 1) [1, 8]. 
When pregnant women travel for long term, it is abso-
lutely necessary that they receive prenatal care in a new 
place of residence. Scheduled maternity care usually begins 
in week 10–12 of pregnancy and continues once a month 
until the 7 month of pregnancy, next it takes place every 
second week until week 36 and then once a week until the 
delivery [9].
According to the American Congress of Obstetricians 
and Gynaecologists, the safest time to travel during preg-
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Table 1. Recommendations for the use of drugs during pregnancy. Source: [8]
Drug name recommendations for use during pregnancy
Analgesics, antipyretics
acetylsalicylic acid 
(aspirin)
Avoid in the third trimester (risk of premature closure of the ductus arteriosus, an increased risk of bleeding)  
NSAIDs (ibuprofen, 
naproxen)
Avoid in the third trimester (the risk of premature closure of the ductus arteriosus, possible coagulation  
disorders; no teratogenic effect)
Antibiotics and antimicrobials
amoxicillin, amoxicillin/ 
/clavulanic acid
Safe during pregnancy, the treatment of upper respiratory tract infections (ear infections, pharyngitis, sinusitis)
azithromycin Safe during pregnancy, recommended for the treatment of bronchitis, pneumonia, gastrointestinal infections 
caused by enterotoxic Escherichia coli, Campylobacter, Salmonella, Shigella
cephalosporins Safe during pregnancy, recommended for the treatment of upper respiratory tract infections (ear infections, 
pharyngitis, sinusitis)
clindamycin (oral or  
external application)
Safe during pregnancy, except for the first trimester; recommended for the treatment of bacterial vaginitis,  
orally or externally, in the second and third trimester; for the treatment of malaria clindamycin is used  
in combination with quinine
ciprofloxacin and  
other quinolones
Avoid during pregnancy; they can be considered for the treatment of severe, life-threatening infections  
(e.g. anthrax)
doxycycline and  
other tetracyclines
Avoid in the second half of pregnancy due to possible developmental dental disorders (permanent tooth  
discoloration)
erythromycin Safe during pregnancy
penicillin Safe during pregnancy
nitrofurantoin First-line therapy for urinary tract infections; avoid in patients with glucose-6-phosphate dehydrogenase  
deficiency (G6PD deficiency)
Antivirals
aciclovir Use only in severe infections
Antidiarrhoeals
loperamide Use on demand in severe cases
bismuth compounds Avoid during pregnancy
Antihistamines
cetirizine Safe during pregnancy
loratadine Safe during pregnancy
Antimalarials
chloroquine Safe during pregnancy, used for the prevention and treatment of malaria
mefloquine Safe during pregnancy, used for the prevention and treatment of malaria
atovaquone/proguanil Avoid in the first trimester; too little clinical data available to confirm the safety of the drug during pregnancy
doxycycline Avoid during pregnancy; it can be used in combination with quinine for the treatment of severe,  
life-threatening infections
quinine Only recommended for the treatment of life-threatening infections
Antiparasitic
albendazole Avoid in the first trimester (teratogenic effect was observed in animal studies); only use in severe cases; if possible, 
start the treatment after the delivery (avoid while breastfeeding, the active ingredient passes into the breast milk)
metronidazole Avoid in the first trimester; only use in severe cases
praziquantel Only use for the treatment of severe schistosomatosis; if possible, start the treatment after the delivery
paromomycin Low drug absorption; recommended for the treatment of severe tapeworm infections as well as Entamoeba 
histolytica or Giardia intestinalis infections
Water disinfectants
iodine Avoid during pregnancy (except for short 2/3-week periods); long-term use may result in the formation of  
foetal goitre and hypothyroidism 
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nancy is the second trimester. Women generally have the 
highest risk of miscarriage during the first trimester. In 
tropical destinations, pregnant women run a higher risk of 
developing medical conditions associated with the effects 
of hot climate (high temperature and humidity), e.g. reduced 
exercise tolerance, increased heart rate associated with an 
increase in plasma volume and anaemia. Intercontinental 
travel during pregnancy is especially contraindicated in the 
following cases [8]:
 — chronic diseases: valvular heart disease, severe anae-
mia, thrombophlebitis; 
 — obstetric contraindications: patients with a  history of 
pregnancy loss, pre-term labour or ectopic pregnancy; 
gestosis, arterial hypertension, history of gestational 
diabetes; imminent abortion or vaginal bleeding during 
pregnancy; primigravida (first pregnancy at the age 
> 35 years or < 15 years);
 — environmental risk factors: high altitude, transmission 
food- and water-borne diseases, malaria endemic areas 
where the resistance of Plasmodium to chloroquine has 
been confirmed, a high risk of the yellow fever trans-
mission, countries where the yellow fever vaccination 
is mandatory.
TrAVELLING bY PLANE
In general, air travel is considered safe for pregnant 
women; however, there are certain legal restrictions in-
volved [10]. For instance, expectant mothers may be re-
quired by the United States airlines to present a medical 
certificate stating they are fit for air travel beyond the 
36th week of pregnancy (domestic flights) or beyond the 
35th week of pregnancy (international flights). Generally, the 
barometric pressure inside passenger aircrafts is reduced 
— equivalent to atmospheric pressure at the altitude of 
1800–2400 m above sea level. Reduced partial pressure 
of oxygen decreases foetal oxygenation to a lesser extent 
than the mother’s blood; this is associated with the presence 
of foetal haemoglobin which has a greater ability to bind 
oxygen molecules than normal haemoglobin. Owing to this 
fact, the risk of foetal hypoxia during air travel is low [11, 12]. 
Due to an increase in plasma volume and the growing mor-
phological demand of the foetus, pregnant women are at 
a higher risk of developing mild anaemia (iron supplements 
are recommended in such cases). In more pronounced 
anaemia (haemoglobin concentration below 8.5 g/dL) air 
travel is contraindicated. In cases when air travel is neces-
sary, the administration of supplemental oxygen should be 
considered. Air travel is considered a health risk for pregnant 
women with sickle-cell anaemia; therefore, they should al-
ways attain approval from their obstetrician before travel. 
The humidity inside airline cabins is low and reaches approx-
imately 8%. Under such conditions, the demand for water 
in pregnant women increases and is estimated at 3–4 L 
per day. Regular intake of decaffeinated beverages is neces-
sary to maintain adequate blood flow to the placenta. During 
long haul flights, when passengers need to remain seated, 
pregnant women run a higher risk of developing deep vein 
thrombosis (DVT), which is associated with the effects of sex 
hormones, compression of blood vessels by the enlarged 
uterus and the impairment of the venous blood flow [13]. 
Thus, it is very important that pregnant women take all 
the necessary measures to prevent DVT, e.g. take a walk 
up and down the aisle every hour, perform isometric exer-
cise of the lower limbs while seated or wear compression 
stockings [14]. Although acetylsalicylic acid (aspirin) exhibits 
antithrombotic effects, it is not recommended in pregnancy, 
especially in the last trimester due to an elevated risk of 
bleeding and its teratogenic effects. Pregnant women with 
a history of thromboembolism or those genetically predis-
posed to such conditions, should contact their obstetrician 
before travelling by plane [8].
TrAVELLING bY sHIP
Pregnant women going on a multiple-day cruise should 
obtain all the necessary information regarding medical as-
sistance available on board (the presence of trained medical 
personnel, specialist equipment, emergency evacuation 
procedures). They also need to keep in mind that treatment 
options for motion sickness are limited during pregnancy 
(a popular drug used to prevent motion sickness containing 
dimenhydrinate is contraindicated during pregnancy and in 
breastfeeding mothers) [15].
VAccINATIONs 
Vaccinations are contraindicated during the first trimes-
ter of pregnancy, i.e. when the foetus is most vulnerable 
to damage [16]. Generally, women are recommended to 
receive all necessary vaccinations before they get pregnant 
(consciously planned motherhood). With only a few excep-
tions, live vaccines are contraindicated during all three 
trimesters of pregnancy (Table 2). The vaccination against 
yellow fever should only be taken if a woman is travelling 
to areas where the risk of the disease transmission is 
particularly high [17]. Pregnant women can abstain from 
vaccination against yellow fever if they travel to areas where 
the risk of transmission is low [1]. On such occasions, they 
may be asked by border guards to present a certificate of 
pregnancy before they can enter a country which normally 
requires the International Certificate of Vaccination from 
international travellers. Similar recommendations on the 
use of live vaccines apply to breastfeeding women. Re-
search studies have demonstrated that the active ingre-
dient present in the yellow fever vaccine penetrates into 
breast milk [8].
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Table 2. Recommendations for vaccinations during pregnancy. Source: [8]
Vaccination against disease recommendations for use
Diphtheria No contraindications for use
Tetanus No contraindications for use
Pertussis No contraindications for use
Hepatitis A Vaccination is only recommended for women at a high risk of infection; no safety data is available on the 
use of the vaccine during pregnancy
Hepatitis B Vaccination is only recommended for women at a high risk of infection
Typhoid fever Vaccination with live attenuated oral vaccine is contraindicated; a polysaccharide vaccine can be used in 
women travelling to disease endemic areas
Cholera Vaccination is not recommended during pregnancy; no safety data is available on the use of the vaccine 
during pregnancy
Poliomyelitis Vaccination with live attenuated oral vaccine (OPV) is contraindicated in pregnant women who have not  
completed the primary vaccination course; inactivated polio vaccine (IPV), used as a booster, is safer than OPV
Meningococcal  
disease
No safety data is available on the use of conjugated vaccine during pregnancy; polysaccharide vaccines 
can only be used if there is a high risk of infection
Rabies Pre-exposure vaccination is only recommended for women at a high risk of infection; post-exposure vac-
cination is recommended during pregnancy
Yellow fever Vaccination is only recommended for women at a high risk of infection; when travelling to countries with 
a low risk of transmission pregnant women can abstain from vaccination, instead, they will be required 
by border guards to present a certificate of pregnancy before they can enter the country
Japanese encephalitis Vaccination is only recommended for women at a high risk of infection; no safety data is available on  
the use of the vaccine during pregnancy
Tick-borne encephalitis Vaccination is not recommended during pregnancy
Measles, Mumps, Rubella Vaccination is contraindicated during pregnancy and three months after giving birth
Varicella Vaccination is contraindicated during pregnancy
MALArIA cHEMOPrOPHYLAXIs 
Malaria is particularly dangerous for a pregnant woman 
and her unborn child [18]. If pregnant women need to travel 
to a malaria endemic destination, they should take all the 
necessary precautions to avoid disease transmission. Wom-
en should avoid becoming pregnant while taking antimalar-
ial drugs as well as after the discontinuation of treatment 
(1 week for doxycycline, 3 weeks for atovaquone/proguanil 
and 3 months for mefloquine). There are no contraindica-
tions for the use of antimalarials in pregnant women travel-
ling to areas with low-to-moderate risk of malaria transmis-
sion (Table 3), i.e. destinations where insect repellents and 
mosquito nets are recommended preventive measures (the 
1st stratum), areas where insect repellents, mosquito nets 
and chloroquine are necessary (the 2nd stratum) and areas 
where insect repellents, mosquito nets and chloroquine 
+ proguanil are required (the 3rd stratum). In destinations 
where the risk of malaria transmission is the highest (the 
4th stratum), pregnant travellers are recommended to re-
ceive mefloquine but it can only be taken during the 2nd and 
3rd trimesters (Table 4) [15]. Doxycycline is contraindicated 
during the whole pregnancy. There is little clinical data on 
the clinical safety of atovaquone/proguanil. As regards 
prevention against insect bites, there are no medical con-
traindications for the use of repellents containing N,N-di-
ethyl-meta-toluamide (DEET) during pregnancy [19]. Clinical 
studies into products containing DEET at a concentration 
of max. 35%, e.g. Permethrin, showed no adverse events 
in pregnant women. Likewise, no adverse effects or devel-
opmental disorders were observed in newborns and infants 
whose mothers had been using DEET-containing repellents 
during pregnancy in the first 12 months after birth [20].
TrEATMENT OF MALArIA
In pregnant women diagnosed with uncomplicated ma-
laria the following drug regimens are recommended: during 
the first trimester: quinine + clindamycin continued for 
7 days; during the second and third trimesters: quinine + clin-
damycin or artesunate + clindamycin continued for 7 days. 
Severe malaria in pregnant women should be treated with 
quinine + clindamycin or artesunate + clindamycin during 
the first trimester (Table 5), and with artesunate in the 
second and third trimesters. Chloroquine is recommended 
for the treatment of P. vivax infections, unless chloroquine 
resistance has been observed. Primaquine, used to prevent 
the recurrence of P. vivax and P. ovale infections, is contrain-
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Table 3. Type of prevention depending on the risk of malaria. Source: [15]
risk stratum risk of malaria transmission recommended prevention
1st stratum Limited risk of malaria transmission Repellents, mosquito nets
2nd stratum Risk of P. vivax transmission only; P. falciparum susceptible to chloroquine Repellents, mosquito nets,  
chloroquine
3rd stratum Risk of both P. vivax and P. falciparum transmission; resistance to chloroquine  
(Nepal, Sri Lanka, Tajikistan, certain regions of Colombia and India)
Repellents, mosquito nets,  
chloroquine + proguanil 
4th stratum High risk of P. falciparum transmission + high antimalarial drug resistance;
Medium/low risk of P. falciparum transmission + high antimalarial drug resistance
In areas with low risk of P. falciparum transmission combined use of repellents and 
stand-by emergency treatment can be considered
Repellents, mosquito nets  
mefloquine 
Table 4. Drugs used for malaria chemoprophylaxis. Source: [15]
Drug name Dosage regimen Duration of chemoprophylaxis Notes 
chloroquine 1 × weekly 
adults: 300 mg 
Start 1week before departure, 1 × weekly 
during travel, continue for 4 weeks after 
return 
Contraindications: epilepsy, psoriasis
chloroquine/ 
/proguanil
1 × daily > 50 kg bw: 
100 mg/200 mg 
Start 1 day before departure, 1 × daily 
during travel, continue for 28 days after 
return
Contraindications: epilepsy, psoriasis
mefloquine 1 × weekly
adults: 250 mg
Start 1 week before departure, 1 × weekly 
during travel, continue for 4 weeks after 
return
Increased serum drug concentration in patients treated 
with ampicillin, tetracyclines and/or metoclopramide
Possible neuropsychiatric adverse reactions
Table 5. Drugs used for the treatment of malaria. Source: [15]
Drug name Dosage regimen
quinine + clindamycin 8 mg/kg bw every 8 h for 7 days 
+ < 60 kg bw: 5 mg/kg bw 4 times a day for 7 days
> 60 kg bw: 300 mg 4 times a day for 7 days
artesunate + clindamycin 2 mg/kg bw artesunate once daily for 7 days
+ 10 mg/kg bw clindamycin twice daily for 7 days
chloroquine 25 mg/kg bw daily divided in 3 doses (10 mg/kg, 10 mg/kg and 5 mg/kg)  
for 3 consecutive days (it is not to be used in P. falciparum infections)
artesunate (severe malaria) 2.4 mg/kg bw IV or IM
0 h (dose 1), 12 h (dose 2), 24 h (dose 3), then once daily
quinine (severe malaria) 20 mg/kg bw IV or IM in 3 doses administered every 8 h (initial dose);
next: 10 mg/kg bw IM in 3 doses administered every 8 h;
note: in case of IV administration the dose cannot exceed 5 mg/kg bw per hour
dicated for use in pregnant women. There is limited clinical 
data on the safety of other malaria treatment regimens in 
pregnant women (artemether/lumefantrine, atovaquone/ 
/proguanil or dihydroartemisinin/piperaquine) [15].
PrEVENTION OF FOOD- AND  
WATEr-bOrNE INFEcTIONs 
When travelling abroad, especially to places lacking 
adequate sanitation, pregnant women should take all the 
necessary precautions to prevent transmission of food and 
waterborne diseases. They should never purchase or con-
sume foods or drinks from local street vendors because it 
is impossible to check their quality (origin, storage, heat-pro-
cessing). If symptoms of a  food or waterborne infection 
do occur (diarrhoea, abdominal pain, fever) and medical 
treatment is necessary, it must be remembered that not 
all medications are safe during pregnancy. Fever and de-
hydration, which are common in traveller’s diarrhoea, can 
impair placental blood flow and thus can have a negative 
effect on foetal development. It is particularly important 
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Table 6. Travel-related infectious diseases, their risk for foetus, and recommended preventive measures. Source: [23]
Disease risk to foetus Preventive measures
Dengue fever Acute febrile illness Insect avoidance
Japanese encephalitis Encephalitis and seizures Pre-pregnancy vaccination, insect avoidance
Leishmaniasis Cutaneous or visceral leishmaniasis Insect avoidance
Hepatitis A Hepatitis Pre-pregnancy vaccination, careful selection of food and water
Typhoid fever Chorioamninitis, spontaneous abortion,  
neonatal sepsis
Vaccination, careful selection of food and water
Toxoplasmosis Chorioretinal lesions, learning disabilities Avoidance of undercooked meats and contact with animal faeces 
Rubella Deafness, cataracts, cardiac defects,  
mental retardation
Pre-pregnancy vaccination, proper hand washing
HIV Congenital and perinatal HIV infection Avoidance of body fluids, blood transfusions, and drug injections
Hepatitis B Hepatitis Pre-pregnancy vaccination, avoidance of body fluids, blood  
transfusions and drug injections
Hepatitis C Hepatitis Avoidance of body fluids, blood transfusions and drug injections
that pregnant travellers take appropriate preventive mea-
sures against infectious and invasive diseases affecting the 
gastrointestinal system, because reduced stomach acidity 
during pregnancy is associated with increased susceptibility 
of the gastric mucosa to pathogens. Toxoplasmosis, listerio-
sis and hepatitis E are particularly dangerous to expectant 
mothers and their unborn children [9]. It is estimated that 
3 of 1000 newborns show signs of congenital toxoplasmosis. 
The risk for the foetus is especially high if the infection devel-
ops during the third trimester of pregnancy. Nearly 50% of 
newborns affected by toxoplasmosis have symptoms of the 
disease as early as at birth. Severe complications, including 
mental impairment, cerebral palsy, deafness and blindness 
are observed in 5–6% of children with congenital toxoplas-
mosis. In order to reduce the risk of toxoplasmosis pregnant 
women should avoid raw or undercooked meat as well as 
contact with potentially infected cat’s faeces, e.g. while 
cleaning a cat’s litter [9]. Also the Listeria infection is danger-
ous for pregnant women. It may be the cause of miscarriage, 
stillbirth or pre-term delivery. Listeria is bacteria found in 
unpasteurised milk and cheeses, such as feta, Brie or Cam-
embert; therefore, expecting mothers should avoid eating 
soft cheeses, especially if they had been manufactured in 
countries with no or little supervision over food production. 
Hepatitis E, usually transmitted through the faecal-oral route, 
is caused by the contamination of water supplies with excre-
ment. The disease poses a great risk for pregnant women 
and can lead to serious health problems including the death 
of both the mother and her unborn child. In non-pregnant 
women, the prevalence of acute hepatitis E infection is less 
than 1%; in pregnant women, however, especially during 
the third trimester, a HEV infection may develop into fulmi-
nant hepatitis with mortality rate reaching 20–30% [21]. 
A vaccine preventing hepatitis E is not yet available but is 
currently under clinical trials. Expectant mothers are not rec-
ommended to travel to areas where hepatitis E is endemic, 
especially to the Indian Subcontinent [15].
PrEVENTION OF THE ZIKA VIrUs INFEcTION
The symptoms of a Zika virus (ZIKV) infection in preg-
nant women are usually mild, but the virus itself can cause 
foetal microcephaly and other congenital abnormalities. 
For this reason, the Centres for Disease Control and Pre-
vention (CDC) recommend pregnant women not travel to 
areas where ZIKV is present and to take precautions to 
avoid sexual transmission of the virus (men are recom-
mended to use condoms for a period of 6 months after 
exposure /return from ZIKV endemic areas; women are 
advised to avoid getting pregnant during travel and to wait 
at least 2 months before trying to conceive after returning 
from endemic region). If a pregnant woman must, for any 
reason, travel to a Zika endemic country, she must strictly 
observe preventive measures against mosquito bites [22]. 
The most current list of countries where ZIKV transmission 
is present is available at the www.cdc.gov/travel website. 
Guidance for pregnant women can be found at the CDC Zika 
website (www.cdc.gov/zika/pregnancy/index.html) [1]. 
PrEVENTION OF OTHEr INFEcTIOUs DIsEAsEs 
Information about prevention of other infectious diseas-
es is presented in Table 6 [23].
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